Optimizing Patient Engagement and Eligible Patient Identification for CAR T-Cell Therapy for DLBCL and FL

Upon completion of this activity, participants should be better able to assess current practice patterns to identify facilitators and barriers to the timely identification of patients eligible for CAR T-cell therapy for diffused large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Upon completion of this activity, participants should be better able to identify patients eligible for CAR T-cell therapy based on non-Hodgkin lymphoma (NHL) subtype, line of therapy, and patient-specific factors to facilitate optimal treatment

Upon completion of this activity, participants should be better able to create interprofessional team-based action plans to close identified gaps in patient engagement and identification of eligible patients with DLBCL and FL for CAR T-cell therapy